Skip to main content

Overview

Overview

Skip to main content

Event Details

Summit Therapeutics Q2 2024 Earnings Call

August 6, 2024 9:00 AM ET

Webcast (opens in new window)

About Summit Therapeutics
Ivonescimab (SMT112)*
Pipeline
Contact

Investor Information
Reports & Filings
Share Price

Visit Linkedin, opens in a new window

Visit X (Formally Twitter), opens in a new window

Visit Facebook, opens in a new window

*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

You are leaving SMMTTX.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

Summit Therapeutics Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

Cancel
Continue

© Summit Therapeutics Inc.

Disclaimer
Privacy Notice
Cookie Preferences
Online Terms of Use

Trademarks, Registered or Otherwise, are the property of their respective owner(s).